CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC

By afschroeder • August 14, 2025

Lee JM, Pujol JL, Zhang J, Leonov O, Tsuboi M, Kim ES, Ng C, Moreno-Mata N, Cummings A, Hacibekiroglu I, Sehitogullari A, Veeramachaneni N, Spillane C, Duan J, Bossen C, Savchenko A, Lobetti-Bodoni C, Mok T, Garrido P. CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC. JTO Clin Res Rep. 2025 Jun 13;6(8):100859. doi: 10.1016/j.jtocrr.2025.100859. PMID: 40810132; PMCID: PMC12343357.

Tags: Hematology/Oncology, Monoclonal antibodies, neoadjuvant treatment, NSCLC, Publications, Pulmonary, Critical Care & Sleep Medicine

Ciprofloxacin and Metronidazole As Rare Culprits of Drug-Induced Immune Thrombocytopenia in the Setting of Diverticulitis Treatment

Tai JW, Young EH, Shah VD, Reed JP. Ciprofloxacin and Metronidazole As Rare Culprits of Drug-Induced Immune Thrombocytopenia in the Setting of Diverticulitis Treatment. Cureus.[...]

Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells

Li YR, Li Z, Zhu Y, Li M, Chen Y, Lee D, Ochoa CJ, Singh T, DiBernardo G, Guo W, Li S, Zhou Y, Yu[...]

Evaluating Asparaginase Toxicity in Hispanic Patients With Acute Lymphoblastic Leukemia in a Large Safety-Net Hospital

Zheng D, Dragan M, Jang J, Tomassetti S. Evaluating Asparaginase Toxicity in Hispanic Patients With Acute Lymphoblastic Leukemia in a Large Safety-Net Hospital. World J[...]